Going into the second month of this new year, biotech investors have a lot to look forward to. In particular, there are many promising drug candidates awaiting approval from the Food and Drug Administration (FDA), as well as a number of well-established drugs that are on the cusp of receiving expanded approval to treat new conditions.
Although there are quite a few drugs being evaluated in the upcoming weeks, not all of them are a big deal. Here are four of the most noteworthy FDA dates that biotech investors should watch out for in February.
Image source: Getty Images.